ARL5B and ovarian carcinoma: highlighted that targeting ARL5B can inhibit the mitochondrial function of ovarian cancer cells, which affects the metabolic reprogramming of tumor cells and consequently inhibits tumor growth, invasion, and metastasis in ovarian cancer (37).